[Gene Silencing in Androgen-Responsive Prostate Cancer Cells]
>>Cancer Research 64, 7661-7663, November 1, 2004
Gene Silencing in Androgen-Responsive Prostate Cancer Cells from the Tissue-Specific Prostate-Specific Antigen Promoter
Jun Song1, Shen Pang1, Yingchun Lu1, Kazunari K. Yokoyama4, Jun-Ying Zheng1 and Robert Chiu1,2,3
1 Dental Research Institute, University of California Los Angeles (UCLA) School of Dentistry, 2 Department of Surgery/Oncology, UCLA School of Medicine, and 3 Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and 4 BioResource Center, RIKEN, Ibaraki, Japan
The success of gene therapy using a RNA interference approach relies on small interfering RNA (siRNA) expression from a highly tissue-specific RNA polymerase II promoter rather than from ubiquitous RNA polymerase III. Accordingly, we have developed a prostate-specific vector that expresses siRNAs from the human prostate-specific antigen promoter, a RNA polymerase II promoter. Our data demonstrate androgen-dependent and tissue-specific siRNA-mediated gene silencing in the androgen-responsive prostate cancer cell line, LNCaP. The biological significance was evidenced by altered apoptotic activity through the inhibition of the apoptosis-related regulatory gene. These results demonstrate that siRNA-mediated gene silencing from a tissue-specific RNA polymerase II promoter could be a potential tool for tissue-specific gene therapy. <<
Cheers, Tuck |
